Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

FineTech Laboratories

FineTech Laboratories?uq=x1rNslWr
1990 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
5 FINANCING ROUNDS
Description

Developer of active pharmaceutical ingredients created to process and polymorph patents by developing non-infringing processes or polymorphs. The company's active pharmaceutical ingredients include cabergoline, latanoprost, travoprost, nabilone, melatonin and methylbenzethonium chloride, enabling the healthcare sectors to access a wide range of products and services to fulfill their needs and develop their sectors under one roof.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Parent Company
Primary Office
  • 33, Hanarkissim Street
  • Nesher 36608
  • Israel

FineTech Laboratories Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore FineTech Laboratories‘s full profile, request access.

Request full access to PitchBook

FineTech Laboratories Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore FineTech Laboratories‘s full profile, request access.

Request full access to PitchBook

FineTech Laboratories Executive Team (1)

Name Title Board
Seat
Contact
Info
Arie Gutman Ph.D Founder, Chief Executive Officer & President